Showing results (1821-1830 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|August 30, 2023
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancerZ Sun, C Gu, X Wang, et al.Investigational New Drugs|March 10, 2009
Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivoQiang Tan, Jing Li, Han-wei Yin, et al.Investigational New Drugs|June 10, 2026
Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330Hamid BelloutInvestigational New Drugs|June 15, 2026
Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemiaLei Deng, Xiaolin Yu, Xiaocheng Song, et al.Investigational New Drugs|January 1, 1986
Phase I clinical study of nafazatromG N Hortobagyi, N E Papadoupoulos, D Frye, et al.Investigational New Drugs|September 4, 2010
17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolismClarence Ahlem, Michael Kennedy, Theodore Page, et al.Investigational New Drugs|July 10, 2026
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System DatabaseConnor FreyInvestigational New Drugs|January 1, 1985
The pharmacokinetics and metabolism of mitoxantrone in manG Ehninger, B Proksch, G Heinzel, et al.Investigational New Drugs|January 1, 1983
Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantroneM S Aapro, D S Alberts, J M Woolfenden, et al.Investigational New Drugs|May 2, 2026
Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysisNihan Küçük Yılmaz, Veysel BaskınPageof 372